Exchange Traded Concepts LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Exchange Traded Concepts LLC increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 164.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,558 shares of the company's stock after purchasing an additional 10,907 shares during the quarter. Exchange Traded Concepts LLC's holdings in Moderna were worth $1,173,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the second quarter worth about $26,000. Cedar Wealth Management LLC increased its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Moderna in the 1st quarter valued at approximately $32,000. Family Firm Inc. acquired a new stake in Moderna in the second quarter valued at $33,000. Finally, Rise Advisors LLC raised its position in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company's stock worth $34,000 after acquiring an additional 286 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ MRNA traded down $2.64 during midday trading on Thursday, hitting $54.82. The company had a trading volume of 5,400,612 shares, compared to its average volume of 4,335,645. The firm has a market capitalization of $21.01 billion, a price-to-earnings ratio of -3.50 and a beta of 1.66. Moderna, Inc. has a twelve month low of $54.82 and a twelve month high of $170.47. The business has a 50-day simple moving average of $71.36 and a two-hundred day simple moving average of $104.92. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company's revenue for the quarter was down 29.9% on a year-over-year basis. During the same period last year, the firm earned ($3.62) EPS. Equities research analysts anticipate that Moderna, Inc. will post -9.85 earnings per share for the current year.

Analysts Set New Price Targets

MRNA has been the subject of a number of research reports. The Goldman Sachs Group reduced their price target on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a research report on Monday, September 16th. Piper Sandler lowered their target price on shares of Moderna from $157.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, September 13th. Evercore ISI reiterated an "in-line" rating and issued a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Oppenheimer downgraded shares of Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. Finally, Bank of America dropped their price target on Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a research report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $97.18.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of the business's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total value of $1,767,000.00. Following the completion of the transaction, the director now directly owns 2,239,015 shares of the company's stock, valued at approximately $263,755,967. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,184 shares of company stock valued at $3,804,931. 15.70% of the stock is owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.